ArticleAnnals of the rheumatic diseases2013
Biosimilars to treat inflammatory arthritis: the challenge of proving identity.
Article in Annals of the rheumatic diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.Rheumatology (Oxford, England) · 2017Trial
- Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.Rheumatology (Oxford, England) · 2017Trial
- A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.Annals of the rheumatic diseases · 2017Trial
- Characteristics and safety outcomes of rheumatoid arthritis patients treated with AMGEVITAArthritis research & therapy · 2026Article
- Safety outcomes in 2132 Danish patients with inflammatory arthritis treated with biosimilar infliximab (GP1111) in routine care.Therapeutic advances in musculoskeletal disease · 2025Article
- The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis.Cureus · 2023Article
- Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis.RMD open · 2022Article
- From Basic Immunology to Clinical Practice: Bio-Originators versus Bio-Similars.Mediterranean journal of rheumatology · 2019Review
- Degree of prescriber's knowledge about variability in biological drugs "innovators" in manufacturing process.European journal of clinical pharmacology · 2018Article
- [Revised version of the statement by the DGRh on biosimilars-update 2017].Zeitschrift fur Rheumatologie · 2018Article
- A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Drug design, development and therapy · 2017Review
- Differentiating biosimilarity and comparability in biotherapeutics.Clinical rheumatology · 2016Review
- Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.Drugs · 2016Review
- The changing landscape of biosimilars in rheumatology.Annals of the rheumatic diseases · 2016Review
- Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.Rheumatology international · 2016Review
- Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example.RMD open · 2016Review
- [Biosimilars in rheumatology. Development and results of clinical trials].Zeitschrift fur Rheumatologie · 2015Review
- Biosimilars in rheumatology: what the clinician should know.RMD open · 2015Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
23897773What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.